Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Muraoka covers the Healthcare sector, focusing on stocks such as SanBio Co, Eisai Co, and Daiichi Sankyo Company. According to TipRanks, Muraoka has an average return of -6.7% and a 28.57% success ...

😎 Tsinghua University, 🥳 Shanghai AI Laboratory (Correspondence: Jingbo Wang and Bo Dai). This work introduces MotionLCM, extending controllable motion generation to a real-time level. Existing ...

Prostate Cancer companies working in the treatment market are Telix Pharmaceuticals, Merck and Orion, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca, Kangpu Biopharmaceuticals, Merus, Blue ...

In August 2025, Biocad conducted a study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...